Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy based on genetically engineered T cells derived from patients. The introduction of CAR T-cell therapy has changed the treatment paradigm of patients with B-cell lymphoid malignancies. However, challenging issues including managing life-threatening toxicities related to CAR T-cell infusion and resistance to CAR T-cell therapy, leading to progression or relapse, remain. This review summarizes the issues with currently approved CAR T-cell therapies for patients with relapsed or refractory B-cell lymphoid malignancies, including lymphoma and myeloma. We focus on unique toxicities after CAR T-cell therapy, such as cytokine-related events and hematological toxicities, and the mechanisms underlying post-CAR T-cell failure.

中文翻译：

---

B 细胞淋巴恶性肿瘤患者嵌合抗原受体 T 细胞治疗的当前挑战。


嵌合抗原受体 （CAR） T 细胞疗法是一种很有前途的免疫疗法，基于源自患者的基因工程 T 细胞。CAR T 细胞疗法的引入改变了 B 细胞淋巴恶性肿瘤患者的治疗模式。然而，具有挑战性的问题仍然存在，包括管理与 CAR T 细胞输注相关的危及生命的毒性和对 CAR T 细胞疗法的耐药性，导致进展或复发。本综述总结了目前批准的 CAR T 细胞疗法治疗复发或难治性 B 细胞淋巴恶性肿瘤（包括淋巴瘤和骨髓瘤）患者的问题。我们专注于 CAR T 细胞治疗后的独特毒性，例如细胞因子相关事件和血液学毒性，以及 CAR T 细胞衰竭后的潜在机制。